The media in the US is corporate in nature, driven by profit and special interests. Would anyone have a problem criticizing the media's deceptiveness regarding the wars in Afghanistan or Iraq? Probably not. We all recognize the influence that the military industrial complex and defense contractors have on Washington legislators and the corporate media. It would no doubt be much more acceptable to you to criticize the media if we were discussing those topics, but if one implies that there is some selective messaging going on with respect to Covid, then suddenly criticizing the media is off limits. Why can we criticize the media in some areas but not others? I find this inconsistent.
The Pharma lobby is one of the most powerful in the US. Of course it is plausible that the corporate media would engage in some selective messaging to turn people away from possible cheap alternatives to Covid, as they turned people towards the idea of WMDs in Iraq, or away from the Public Option (it would run insurance companies out of business, right?), and as the media seeks to shape the narrative around a myriad of other issues (universal healthcare, UBI, certain political ideas that fall outside of the status quo, etc). It's "manufactured consent", as Noam Chomsky puts it.
The narrow dialogue and fixation on classifying Ivermectin as only a horse dewormer is reflective of this. The corporate media rarely mentions that Ivermectin is a safe drug that has been used worldwide for decades, nor will they mention the study that I had to proactively search out to begin to understand the full picture. Instead, the media hypes up the cases of people who misuse the drug, which is a small minority. Omit any news about Ivermectin to the contrary, and voila - manufactured consent. It's selective and self serving messaging, with an obvious objective of tarring as fringe elements those who might want to discuss Ivermectin. This in turn gives license to those who blithely follow this narrative to ridicule those who they perceive as ignorant and uninformed. In the context of what they have been led to believe, this self righteous condescension is logical, but they're missing the bigger picture.
These are the sections from the study that I found most relevant:
1. Ivermectin is a well-known medicine that is approved as an antiparasitic by the World Health Organization and the US Food and Drug Administration. It is widely used in low- and middle-income countries (LMICs) to treat worm infections. 2,3 Also used for the treatment of scabies and lice, it is one of the World Health Organization’s Essential Medicines.4 With total doses of ivermectin distributed apparently equaling one-third of the present world population,5 ivermectin at the usual doses (0.2–0.4 mg/kg) is considered extremely safe for use in humans. 6,7 In addition to its antiparasitic activity, it has been noted to have antiviral and anti-inflammatory properties, leading to an increasing list of therapeutic indications.8
2. A review by the Front Line COVID-19 Critical Care Alliance summarized findings from 27 studies on the effects of ivermectin for the prevention and treatment of COVID-19 infection, concluding that ivermectin “demonstrates a strong signal of therapeutic efficacy” against COVID-19. 9 Another recent review found that ivermectin reduced deaths by 75%. 10
3. Ivermectin has exhibited antiviral activity against a wide range of RNA and some DNA viruses, for example, Zika, dengue, yellow fever, and others. 13 Caly et al 14 demonstrated specific action against SARSCoV-2 in vitro with a suggested host-directed mechanism of action being the blocking of the nuclear import of viral proteins 14,15 that suppress normal immune responses.
4. Developing new medications can take years; therefore, identifying existing drugs that can be repurposed against COVID-19 that already have an established safety profile through decades of use could play a critical role in suppressing or even ending the SARS-CoV2 pandemic. Using repurposed medications may be especially important because it could take months, possibly years, for much of the world’s population to get vaccinated, particularly among LMIC populations.
5. All-cause mortality: Meta-analysis of 15 trials, assessing 2438 participants, found that ivermectin reduced the risk of death by an average of 62% (95% CI 27%–81%) compared with no ivermectin treatment [average RR (aRR) 0.38, 95% 0.19 to 0.73; I 2 5 49%]; risk of death 2.3% versus 7.8% among hospitalized patients in this analysis, respectively (SoF Table 2 and Figure 3).
6. The effect on reducing deaths was consistent across mild to moderate and severe disease subgroups.
7. The cumulative z-curve in Figure 8 crossed the trial sequential monitoring boundaries after reaching the required IS, implying that there is firm evidence for a beneficial effect of ivermectin use over no ivermectin use in mainly hospitalized participants with mild to moderate COVID-19 infection.
8. The findings indicate with moderate certainty that ivermectin treatment in COVID-19 provides a significant survival benefit.
9. In addition to the evidence from systematic reviews, the findings of several controlled observational studies are consistent with existing evidence and suggest improved outcomes with ivermectin treatment.55,57,59 Similarly, with respect to ivermectin prophylaxis of frontline workers and those at risk, controlled observational studies from Bangladesh and Argentina (the latter which involved 1195 health care workers) have shown apparent reductions in COVID-19 transmission with ivermectin prophylaxis, including in some reports total protection (zero infections) where infection rates in the control group exceeded 50%. 122,
10. There is also evidence emerging from countries where ivermectin has been implemented. For example, Peru had a very high death toll from COVID-19 early on in the pandemic. 128 Based on observational evidence, the Peruvian government approved ivermectin for use against COVID-19 in May 2020. 128 After implementation, death rates in 8 states were reduced between 64% and 91% over a two-month period. 128 Another analysis of Peruvian data from 24 states with early ivermectin deployment has reported a drop in excess deaths of 59% at 30+ days and of 75% at 45+ days. 129
11. Certain South American countries, Indian states, and, more recently, Slovakia and other countries in Europe have implemented its use for COVID-19. 129,131,132,133,134
12. Given the evidence of efficacy, safety, low cost, and current death rates, ivermectin is likely to have an impact on health and economic outcomes of the pandemic across many countries. Ivermectin is not a new and experimental drug with an unknown safety profile. It is a WHO “Essential Medicine” already used in several different indications, in colossal cumulative volumes. Corticosteroids have become an accepted standard of care in COVID-19, based on a single RCT of dexamethasone. 1 If a single RCT is sufficient for the adoption of dexamethasone, then a fortiori the evidence of 2 dozen RCTs supports the adoption of ivermectin.
13. Ivermectin is likely to be an equitable, acceptable, and feasible global intervention against COVID-19. Health professionals should strongly consider its use, in both treatment and prophylaxis.